Ключевые слова
Как цитировать
Аннотация
Прогрессирование рака желудка после радикального лечения является крайне неблагоприятным фактором, определяющим дальнейший прогноз жизни пациента. При этом канцероматоз брюшины - наиболее частый вариант прогрессирования, при котором возможности системной химиотерапия весьма ограничены. Современные же методы внутрибрюшинной химиотерапии при раке желудка и перитонеальном канцероматозе применяются, однако их эффективность достаточно ограничена. Профилактика развития канцероматоза могло бы уменьшить частоту прогрессирования, тем самым улучшить прогнозы после радикального лечения при неметастатическом местно-распространенном раке желудка. Роль профилактической внутрибрюшинной химиотерапии в лечении неметастатического рака желудка является областью продолжающихся исследований. Представленный обзор литературы освещает исследования, касаемые имеющихся регионарных методов внутрибрюшинной химиотерапии, применяющихся с целью профилактики перитонеального канцероматоза в процессе комбинированного радикального лечения рака желудка с высоким риском канцероматоза брюшины. Проведен поиск литературы по базам данных Scopus, Web of Science, PubMed, РИНЦ. При анализе использованы источники, индексируемые в базах данных Scopus и Web of Science (99%), РИНЦ (1%), а также базы данных клинических исследований Национальной медицинской библиотеки (NLM) ClinicalTrials.gov и реестра клинических испытаний США ICH GCP.
Более 50 % работ опубликованы за последние 5 лет. Для написания данного литературного обзора было использовано 48 источников.
Библиографические ссылки
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):19481957. doi:10.1016/S0140-6736(18)32557-1.
Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402. doi:10.1177/1758835919846402.
Gockel I, Jansen-Winkeln B, Haase L, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): Results of a single-center experience and register study. J Gastric Cancer. 2018;18(4):379391. doi:10.5230/jgc.2018.18.e37.
Dineen SP, Pimiento JM. The landmark series: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for treatment of gastric cancer metastatic to peritoneum. Ann Surg Oncol. 2021;28(8):41304137. doi:10.1245/s10434-021-09927-7.
Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73. doi:10.1186/s12885-015-1081-8.
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717726. doi:10.1016/S1470-2045(16)00175-3.
Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021;12(Suppl 1):S32S44. doi:10.21037/jgo-2020-04.
Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27(2):1538. doi:10.1007/s00268-002-6279-7.
Yonemura Y, Bandou E, Kinoshita K, et al. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am. 2003;12(3):63548. doi:10.1016/s1055-3207(03)00035-8.
Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Annals of Surgical Oncology. 2005;12(5):347353. doi:10.1245/aso.2005.03.065.
Homma Y, Ushida S, Yamada M, et al. Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol. 2010;17(2):45560. doi:10.1245/s10434-009-0764-2.
Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res. 2003;9(2):67885.
Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):1226. doi:10.1016/j.ejso.2013.10.019.
Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):8597. doi:10.4251/wjgo.v2.i2.85.
Iitsuka Y, Kaneshima S, Tanida O, et al. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer. 1979;44(4):1476-80. doi:10.1002/1097-0142(197910)44:4<1476::aid-cncr2820440442>3.0.co;2-r.
Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):270213. doi:10.1245/s10434-007-9487-4.
Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250(2):2426. doi:10.1097/SLA.0b013e3181b0c80e.
Kim G, Chen E, Tay AY, et al. Extensive peritoneal lavage after curative gastrectomy for gastric cancer (EXPEL): study protocol of an international multicentre randomised controlled trial. Jpn J Clin Oncol. 2017;47(2):179184. doi:10.1093/jjco/hyw153.
Misawa K, Mochizuki Y, Sakai M, et al. Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial). Br J Surg. 2019;106(12):16021610. doi:10.1002/bjs.11303.
Batista TP, Martins MR, Martins-Filho ED, et al. A phase ii trial exploring the extensive intra-operative peritoneal lavage (EIPL) as a prophylactic strategy for peritoneal recurrence in locally advanced gastric cancer: reporting postoperative morbidity and mortality after early closure. Arq Gastroenterol. 2015 52(2):1614. doi:10.1590/S0004-28032015000200017.
Guo J, Xu A, Sun X, et al. Combined surgery and extensive intraoperative peritoneal lavage vs surgery alone for treatment of locally advanced gastric cancer: The SEIPLUS randomized clinical trial. JAMA Surg. 2019;154(7):610616. doi:10.1001/jamasurg.2019.0153.
Tao W, Liu X-Y, Cheng Y-X, et al. Does extended intraoperative peritoneal lavage really bring benefit on patients with gastric cancer? a meta-analysis of published clinical trials. Front Oncol. 2021;11. doi:10.3389/fonc.2021.715040
Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21(4):23348. doi:10.1002/ssu.10042.
Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl 6):8397.
Goodman MD, McPartland S, Detelich D, et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):4557. doi:10.3978/j.issn.2078-6891.2015.111.
Morgan RJ Jr, Synold TW, Xi B, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13(4):12327. doi:10.1158/1078-0432.CCR-06-1735.
Seshadri RA, Glehen O. The role of hyperthermic intraperitoneal chemotherapy in gastric cancer. Indian Indian J Surg Oncol. 2016;7(2):198–207. doi:10.1007/s13193-016-0502-8.
Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61(2):2327. doi:10.1002/1097-0142(19880115)61:2<232::aid-cncr2820610205>3.0.co;2-u.
Brenkman HJF, Päeva M, van Hillegersberg R, et al. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-a systematic review. J Clin Med. 2019;8(10):1685. doi:10.3390/jcm8101685.
Beeharry MK, Zhu ZL, Liu WT, et al. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer. 2019;19(1):932. doi:10.1186/s12885-019-6125-z. Erratum in: BMC Cancer. 2019;19(1):1256.
Lee TY, Hsu CH, Fan HL, et al Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022;48(9):19721979. doi: 10.1016/j.ejso.2022.04.018.
Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:114. doi:10.1016/j.ejca.2017.03.030.
Sun J, Song Y, Wang Z et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 12, 2012;12(1):526. doi:10.1186/1471-2407-12-526.
Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183. https://doi.org/10.1186/1471-2407-14-183
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier: NCT03917173, Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Gastric Carcinoma.GOETH Study (GOETH). [last updated June 18, 2021]; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03917173
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04597294, Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence (CHIMERA); [last updated 2022 Nov 14]; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04597294.
Götze TO, Piso P, Lorenzen S, et al. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer. 2021;21(1):1158. doi:10.1186/s12885-021-08872-8.
Vanounou T, Garfinkle R. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine. Ann Surg Oncol. 2016;23(8):2556–61. doi:10.1245/s10434-016-5096-4.
Huo YR, Richards A, Liauw W, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–89. doi:10.1016/j.ejso.2015.08.172.
Mehta SS, Gelli M, Agarwal D et al. Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. Indian J Surg Oncol. 2016;7(2):2259. doi:10.1007/s13193-016-0504-6.
Kelly KJ, Nash GM. Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma. J Surg Oncol. 2014;109(1):1422. doi:10.1002/jso.23449.
Kodera Y, Imano M, Yoshikawa T, et al. A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). Jpn J Clin Oncol. 2011;41(2):2836. doi:10.1093/jjco/hyq187.
Mi D-H, Li Z, Yang K-H, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: A systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia. 2013;29(2):156–67. doi:10.3109/02656736.2013.768359.
Beeharry MK, Zhu ZL, Liu WT, et al. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer. 2019;19(1):932. doi:10.1186/s12885-019-6125-z. Erratum in: BMC Cancer. 2019;19(1):1256.
Imano M, Imamoto H, Itoh T, et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur Surg Res. 2011;47(4):2549. doi:10.1159/000333803.
Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat. 2014;46(3):2709. doi:10.4143/crt.2014.46.3.270.
Kitayama J, Ishigami H, Yamaguchi H, et al. Intraperitoneal Paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure. Case Rep Oncol. 2014;7(1):5864. doi:10.1159/000358379.
Peng YF, Imano M, Itoh T, et al. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol. 2015;111(8):10416. doi:10.1002/jso.23928.
Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):6770. doi:10.1093/annonc/mdp260.
Takahashi N, Kanda M, Yoshikawa T, et al. A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. Gastric Cancer. 2018;21(6):1014–23. doi:10.1007/s10120-018-0817-y.
Ishigami H, Tsuji Y, Shinohara H, et al. Intraperitoneal chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 Trial. J Clin Med. 2021;10(23):5666. doi:10.3390/jcm10235666.
Tempfer CB, Solass W, Buerkle B, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: a case report. Gynecol Oncol Rep. 2014;10:325. doi:10.1016/j.gore.2014.10.001.
Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):5539. doi:10.1245/s10434-013-3213-1.
Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368e377. doi:10.1016/S1470-2045(19)30318-3.
Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019:1758835919846402. doi:10.1177/1758835919846402.
Khomyakov V, Ryabov A, Ivanov A, et al. Results of systemic chemotherapy in combination with pressurized intraperitoneal aerosol chemotherapy in patients with gastric cancer and synchronous peritoneal carcinomatosis. P.A. Herzen Journal of Oncology. 2022;11(2):5. doi:10.17116/onkolog2022110215.
Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):36773. doi:10.1007/s11605-015-2995-9.
Alyami M, Bonnot PE, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47(1):123127. doi:10.1016/j.ejso.2020.05.021.
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04047004, Adjuvant PIPAC in Gastric Cancer Patients (PIPAC-OPC4); [last updated 2022 Oct 6]; [about 6 screens]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04047004.
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04410887, Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC); [last updated 2020 June 1]; [about 6 screens]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04410887.
Reid JL, Kanhere HA, Hewett PJ, et al. Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. Pleura Peritoneum. 2021;6(4):151154. doi:10.1515/pp-2021-0132.
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04595929, Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- (GASPACCO); [last updated: November 25, 2020]; [about 9 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04595929.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2023